Human Cord Blood-CD34+ Hematopoietic Stem Cell from Ace Therapeutics are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube and are cryogenically preserved.

Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC From Adipose Mesenchymal Stromal Cells from Ace Therapeutics are generated using an episomal reprogramming containing a proprietary mix of vectors, containing Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1. The cell line was validated for pluripotency based on colony morphology, alkaline phosphatase expression, and expression of SSEA-4.iPS colonies exhibit classical morphology and growth.

The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

Human Neural Stem Cells (HNSC) are self-renewing, generated throughout an adult’s life via neurogenesis. These multipotent adult stem cells generate the main phenotype of the nervous system, differentiating into neurons, astrocytes, and oligodendrocytes. Ace Therapeutics's Human Neural Stem Cells-cortex region are cells derived from the cortex region of human brain (single donor). They are cryopreserved at first passage. Our HNSC stain positive for β-tubulin III, GFAP and oligodendrocyte marker O4 when cultured in Human Neural Differentiation Medium for 10 days. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC Line (Episomal, PBMC) from Ace Therapeutics was derived from human mesenchymal stromal cells (MSCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.

CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

Human endothelial progenitor cells (EPCs) are circulating cells that exhibit a range of cell surface markers comparable to those found on vascular endothelial cells. They encompass primitive endothelial cells that possess enhanced angiogenic and vasculogenic characteristics. These primitive endothelial cells have the remarkable capacity to proliferate and undergo differentiation, ultimately maturing into functional endothelial cells. Human Endothelial Progenitor Cell from Ace Therapeutics can be expanded for up to 120 population doublings or 12 passages, providing ample material for experimentation. They express positive markers such as CD31, CD144, (VEGF)R2, CD146, CD73, CD105, and exhibit the uptake of acetylated low-density lipoprotein. Furthermore, AcceGen provides one million viable cells upon thawing of the frozen vial, which is shipped in dry ice to maintain cell integrity during transportation.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.